Back to results
US 2019/0169159 A1Published application
Metalloenzyme Inhibitor Compounds
AssigneeMycovia Pharmaceuticals, Inc.
InventorsWilliam J. Hoekstra, Robert J. Schotzinger, Stephen W. Rafferty
Life of this patent
Estimating the term…
Abstract
The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
Claims28
A compound of Formula I, or salt thereof, wherein:
- MBG is tetrazolyl;
- R1 is halo;
- R2 is halo;
- R3 is independently halo, haloalkoxyalkyl, or hydroxyl;
- R4 is aryl, optionally substituted with 0, 1, 2 or 3 independent R3;
- R5 is H or —P(O)(OH)2;
- R6 is halo;
- and
- n is 0, 1, 2 or 3.
6 more elements
2-3. (canceled)
13-26. (canceled)
28-37. (canceled)
39-49. (canceled)
A compound of Formula I, or salt thereof, wherein:
- MBG is tetrazolyl;
- R1 is halo;
- R2 is halo;
- R3 is independently independently halo or haloalkoxyalkyl;
- R4 is aryl, optionally substituted with 0, 1, 2 or 3 independent R3;
- R5 is —P(O)(OH)2;
- R6 is hydrogen;
- and
- n is 0, 1, 2 or 3.
6 more elements
51-52. (canceled)
The compound of claim 13, wherein:
- R1 and R2 are fluoro;
- R3 is 2,2,2-trifluoroethoxy, and n is 1;
- R4 is difluorophenyl;
- and
- R5 and R6 are hydrogen.
2 more elements
A compound of Formula I, or salt, solvate, hydrate or prodrug thereof, wherein:
- MBG is tetrazolyl;
- R1 is fluoro;
- R2 is fluoro;
- R3 is haloalkoxyalkyl;
- R4 is phenyl substituted with 1, 2, or 3 fluoro;
- R5 is hydrogen;
- R6 is hydrogen;
- and
- n is 1.
6 more elements
Dependencies are inferred from the claim text.